# RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy

> **NCT03524430** · NA · RECRUITING · sponsor: **Rna Diagnostics Inc.** · enrollment: 801 (estimated)

## Conditions studied

- Breast Neoplasm Female

## Interventions

- **PROCEDURE:** Core needle biopsy

## Key facts

- **NCT ID:** NCT03524430
- **Lead sponsor:** Rna Diagnostics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-04-26
- **Primary completion:** 2026-07-30
- **Final completion:** 2031-03-31
- **Target enrollment:** 801 (ESTIMATED)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03524430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03524430, "RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03524430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*